Financial support and sponsorship This work was supported by the Natural Science Basic Research Program of Shaanxi Province (#2023-JC-QN-0239), the National Department of Education Central Universities Research Fund (#GK202207004), the University-Industry Collaborative Education Program (#231005940204433) to Wang LY, and the National Natural Science Foundation of China (#82000512) to Huang YM
Additional exploratory applications include neuroprotection through enhanced brain energy metabolism and immune modulation, as preliminary work suggests anti-inflammatory actions in experimental models
Sources MOUNJARO (tirzepatide) Injection, for subcutaneous use (2022) Zepbound (tirzepatide) Injection, for subcutaneous use (2022) FDA News Release: FDA Approves First Medication for Obstructive Sleep Apnea (December 20, 2024) Tirzepatide Once Weekly for the Treatment of Obesity (June 4, 2022) Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (June 21, 2024)
Are non-surgical treatments effective for mild loose skin
doi: 10.1016/j.jemermed.2022.12.016
